Economic Evaluation and Catheter-related Bloodstream Infections by Halton, Kate & Graves, Nicholas
Catheter-related bloodstream infections are a serious 
problem. Many interventions reduce risk, and some have 
been evaluated in cost-effectiveness studies. We review the 
usefulness and quality of these economic studies. Evidence 
is incomplete, and data required to inform a coherent policy 
are missing. The cost-effectiveness studies are character-
ized by a lack of transparency, short time-horizons, and nar-
row economic perspectives. Data quality is low for some 
important model parameters. Authors of future economic 
evaluations should aim to model the complete policy and 
not just single interventions. They should be rigorous in de-
veloping the structure of the economic model, include all 
relevant economic outcomes, use a systematic approach 
for selecting data sources for model parameters, and propa-
gate the effect of uncertainty in model parameters on con-
clusions. This will inform future data collection and improve 
our understanding of the economics of preventing these 
infections.
C
atheter-related bloodstream infections (CR-BSI) occur 
at an average rate of 5 per 1,000 catheter days in inten-
sive-care units in the United States (1), resulting in 80,000 
episodes of CR-BSI per year (2). This situation leads to in-
creased patient illness, length of stay, and costs of care (3,4) 
and possibly additional deaths (5). Empiric evidence (6) 
suggests that >50% of these infections could be prevented. 
The evidence for the effectiveness of numerous single and 
multimodule interventions has been reviewed (2,7), leav-
ing the decision maker with the complex task of selecting 
the best infection-control programs. This decision should 
be informed by data on the effectiveness of an intervention 
as well as an understanding of the cost implications (8).
An effective strategy that reduces the risk for CR-
BSI will generate health beneﬁ  ts from avoided illness and 
possibly reduced deaths. At the same time, preventing in-
fections will save costs, and these are offset against cost 
increases from implementing the strategy. The aggregate 
of these costs will be either positive (cost-increasing) or 
negative (cost-saving). An effective program that saves 
costs must be implemented so as not to waste resources and 
harm patients at the same time. An effective program that 
increases costs should be subject to a cost-effectiveness 
test (e.g., <$50,000 per life year gained) and, if successful, 
it should be given serious consideration by policymakers. 
This information can be found in full economic evaluations 
in which changes to costs and health beneﬁ  ts for a novel 
strategy are compared with a relevant comparator such as 
current practice (8,9). This enables us to identify the course 
of action that offers optimal returns from our investment of 
resources.
With the current spending on healthcare in the United 
States being >15% of the gross domestic product (10), the 
US Food and Drug Administration, as well as the regu-
latory agencies for the United Kingdom, Australia, and 
Canada, now require additional programs or therapies to 
demonstrate cost-effectiveness. The message is clear: new 
healthcare investments should promote efﬁ  ciency in re-
source allocation, not detract from it.
The existing economics literature for CR-BSI includes 
2 approaches to full economic evaluation. First are trial-
based evaluations in which values for parameters such as 
costs and health beneﬁ  ts are derived from a single data-
collection exercise. Second are modeling studies for which 
values for these parameters are obtained from a variety of 
sources and combined in a decision-analytic model. The 
advantages and disadvantages of each have been discussed 
(11). A major advantage of model-based evaluations is the 
ability to include long-term cost and death outcomes not 
observed within the period of a clinical trial. Also, inter-
ventions that have not been or cannot be directly compared 
in a clinical trial can be evaluated side by side in modeling 
studies. These evaluations allow consideration of all rele-
vant competing infection control interventions and not just 
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a single novel strategy compared with existing practice. Fi-
nally, model-based evaluations are more generalizable and 
can be used to evaluate the cost-effectiveness of an inter-
vention in a real-life context not represented by the results 
of a trial. For these reasons they are the increasingly the 
preferred approach to the economic evaluation of health-
care interventions (12). However, care is needed and only 
high-quality, appropriately designed and unbiased models 
should be published and used for policymaking (11).
The aims of our study are to summarize the existing 
literature on model-based economic evaluation of interven-
tions to prevent CR-BSI and then critique this literature, fo-
cusing on 2 questions. 1) How useful are the evaluations in 
terms of how the research questions and ﬁ  ndings align with 
the information needed to make good decisions? 2) What 
is the quality of the evaluations, in particular, whether the 
quality of the model structure, the source of parameter data 
and its incorporation into the model, and the techniques 
used to evaluate the model are such that the evidence pro-
vided is convincing to decision makers? Ultimately, we aim 
to judge the value of this body of literature in helping us 
understand the economics of preventing CR-BSI and iden-
tify priorities for future research that will lead to a deeper 
understanding of this topic.
Methods
We reviewed data published between 1990 and No-
vember 2005. Searches were conducted in Medline, the 
Cumulative Index to Nursing and Allied Health Literature, 
Biologic Abstracts, Academic Search Elite, and Econ-
lit by using the medical subject headings catheterization 
central venous, costs and cost analysis, and infection; or 
text keywords catheter and central, cross-referenced with 
infection, bacteremia, or sepsis, and cost-effective, cost-
beneﬁ  t, or cost-utility. We searched the Centre for Reviews 
and Dissemination databases (www.york.ac.uk/inst/crd) by 
using the same subject keywords and limiting the search 
to economic evaluations. In addition, the reference lists of 
retrieved articles and review articles in this ﬁ  eld of research 
(13–16) were searched to identify published articles that 
met predeﬁ  ned inclusion and exclusion criteria (Table 1).
To assess the usefulness of the economic evaluations 
included, summary data for each were extracted by us-
ing an audit tool based on the Harvard Cost-Effectiveness 
Analysis Registry data abstraction forms (17). The data 
extracted included a description of the intervention(s) and 
population studied, the research question, the structure of 
the economic model and assumptions used, the data used 
to inform model parameters, the outcomes considered, and 
the results and conclusions, including the results of sensi-
tivity analyses. All US dollar ﬁ  gures were adjusted to 2005 
prices by using the Bureau of Labor Statistics Consumer 
Price Index speciﬁ  c to Medical Care (www.bls.gov/cpi), al-
though any common year could have been assumed. When 
the cost year used for the analysis was not stated, it was 
assumed to be 1 year before publication. This assumption 
will not affect evaluation of the analysis.
To assess the quality of the economic evaluations, we 
used a set of good practice criteria for decision analytic 
modeling (18). Four criteria are used to assess the structure 
of the model; 6 criteria to assess how data were sourced and 
incorporated, including approaches to sensitivity analysis; 
and 1 criterion to judge how the model was evaluated in 
terms of its own consistency. These 11 criteria were applied 
as a series of questions that focused on the relevance and 
coherence of the modeling approach taken in each evalua-
tion, rather than as a prescriptive checklist.
The quality of the data used to inform model param-
eters was also assessed by using the modiﬁ  ed version (19) 
of the potential hierarchies of data sources for economic 
analyses (20). Each component of the decision model was 
assessed: clinical effect size, baseline clinical data, adverse 
events, resource use, costs, and utilities. The quality of data 
sources is ranked from 1 to 6 with the highest quality of ev-
idence ranked 1. Rankings for evidence pertaining to clini-
cal effect size are comparable with the concept of levels 
of evidence as used in evidence-based medicine (21) and 
Cochrane reviews (22). For each article, the highest level of 
evidence used for each parameter was recorded.
Results
A total of 106 abstracts were identiﬁ  ed, and 8 met the 
inclusion criteria (23–30). The reasons for exclusion are 
shown in the Figure.
Usefulness of Evaluations
Six interventions were evaluated (Table 2); antimi-
crobial drug–coated catheters were included in 3 separate 
analyses (27,29,30). One intervention was compared with 
current practice for all studies, except those of Shorr et al. 
(29) and Ritchey et al. (28), who evaluated 3 types of an-
timicrobial drug–coated catheter and 3 different catheter 
replacement regimens, respectively. No direct comparisons 
were made across intervention types, e.g., use of an antisep-
tic catheter versus introduction of chlorhexidine as a skin 
preparation, and no evaluations assessed multiple concur-
rent interventions or bundles. The authors of 6 evaluations 
(23,24,26,27,29,30) found the intervention to be effective 
in preventing CR-BSI and cost-saving (Table 3), and the 
authors of 2 other evaluations (25,28) generated data to cal-
culate incremental cost-effectiveness ratios.
Sensitivity analysis was performed in addition to 
baseline analysis in 5 evaluations (23,26,27,29,30). This 
provided decision makers with information on the robust-
ness of baseline results to different parameter estimates or 
characterized the effect of uncertainty in model parameters Economics of Catheter-related Bloodstream Infections
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on the results (23,27,30). In 3 cases (24,25,28), sensitiv-
ity analysis formed the main body of the evaluation, and 
decision makers faced multiple sets of results arising from 
different parameter estimates.
Quality of Economic Evaluations
The extent to which the quality criteria were met for 
the studies varied from 1/8 for checks on the internal con-
sistency to 8/8 for description of strategies/comparators. 
This assessment is shown in Table 4.
Model Structure
All authors provided a clear description of the interven-
tion and speciﬁ  ed the economic perspective used, which in 
all cases was that of the hospital or healthcare payer rather 
than a societal perspective. Only Shorr et al. (29) justiﬁ  ed 
their choice of perspective. In 7 evaluations (23,24,26–30), 
a decision tree was used, with a diagram provided in all 
but 1 report (26). In another evaluation (25), a regression 
model was used, and only the formula used for the base-
line analysis, not the extension used for sensitivity analysis, 
was provided. Authors of only 4 evaluations discussed the 
evidence or expert opinion used to develop the structure of 
the model (23,27,29,30).
Each evaluation used a different representation of the 
disease pathway in terms of the timing and nature of the 
relevant clinical events. For example, 1 evaluation modeled 
colonization as an event preceding CR-BSI (23), 4 consid-
ered these as mutually exclusive events (24,26,27,30), and 
3 did not consider colonization (25,28,29). Two models in-
cluded adverse events speciﬁ  c to the intervention (28,30), 
but this was not consistent across studies, with only 1 of the 
3 evaluations of antiseptic-impregnated catheters includ-
ing incidence of hypersensitivity reactions to the catheter 
(30). In 7 evaluations (23–26,28–30), only the outcomes 
that would arise during the period of hospitalization were 
included. In another evaluation (27), the time horizon de-
scribed the patient’s lifetime.
Source and Incorporation of Data
Authors of all evaluations stated the baseline data used 
in the model along with its source; 5 had information in 
a table format (23,24,27,29,30). Most parameter estimates 
came from the published literature, although 5 evaluations 
performed their own cost calculations for the intervention 
(23–26,29) and 1 used original patient trial data for the es-
timates of daily incidence and relative risk for infectious 
events (27). Seven evaluations (23,25–30) discussed sim-
plifying assumptions and issues of generalizability.
For 6 evaluations (23,26–30), the most important mod-
el parameters were identiﬁ  ed (Table 5), with the following 
3 parameters consistently important: reduction in risk for 
CR-BSI caused by the intervention, baseline incidence of 
CR-BSI, and cost of treating a CR-BSI. The ranks of evi-
dence used for these and other model parameters are shown 
Table 1. Inclusion and exclusion criteria for review 
Inclusion criteria 
Had a full publication or manuscript for review 
Conducted a full economic evaluation which valued both costs 
and benefits of the intervention 
Based on a decision-analytic model 
Evaluated at least 1 infection-control intervention aimed at 
reducing incidence of catheter-related bloodstream infection 
relative to a baseline scenario 
Evaluated the intervention with respect to short-term (<21 d), 
nontunneled, central venous catheters 
Based in an adult patient population 
Written in English 
Exclusion criteria 
Cost-analysis studies only 
Did not use a comparator 
Based on a clinical trial (e.g., randomized controlled trial or 
pre-post intervention study) or a case study 
Did not contain an original analysis (e.g., editorials, reviews) 
Contained purely hypothetical data (e.g., methods articles) 
Did not provide full details on methods (e.g., letters) 
Based in a pediatric patient population 
Evaluated interventions aimed at long-term or tunneled or 
peripherally placed central venous catheters 
Evaluated therapeutic or diagnostic interventions, as opposed 
to preventive interventions 
Figure. Reports included in the review. CR-BSI, catheter-related 
bloodstream infections. The 19 economic evaluations excluded 
from the review are shown in the online Appendix (available from 
www.cdc.gov/EID/content/13/6/817-app.htm). PERSPECTIVE
818  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 6, June 2007
in Table 6. The level of evidence used for the effective-
ness of the intervention was generally high, and authors of 
all evaluations provided information on how they selected 
the data used for this parameter. However, the level of evi-
dence used for the cost and baseline incidence of CR-BSI 
was generally of lower quality; little detail was given in 
the reports of the evaluations as to why 1 particular esti-
mate for a parameter was chosen over another. In particu-
lar, in all evaluations, reference was made in the introduc-
tion or discussion section to relevant information on the 
cost and deaths attributable to CR-BSI that was not used in 
the analysis. This explains the wide variation in the source 
and value of the estimates used for parameters between the 
evaluations (Table 5).
Model parameters were expressed as probability dis-
tributions for only 3 studies (23,27,30), even though this 
method provided an opportunity to appropriately describe 
parameter uncertainty. All 3 studies speciﬁ  ed the choice of 
distribution for model parameters and the rationale for this 
choice. The remaining studies (24–26,28,29) used point es-
timates and a range for each parameter across which the 
estimate was varied in sensitivity analyses. Similar to the 
baseline estimates, no information was given on how rang-
es used for sensitivity analysis were decided upon, aside 
from a double-it and half-it approach.
Model Evaluation
All evaluations used deterministic sensitivity analy-
ses by varying parameters across a range of point esti-
mates either 1 at a time (1-way) or concurrently (multi-
way). Four studies (25,28–30) reported results of threshold 
analyses, i.e., the value of each parameter at which the 
Table 2. Summary of economic evaluations of interventions to prevent CR-BSI included in the review* 
Intervention Comparator Analysis Perspective
Sensitivity 
analysis  Time horizon Hospitalized patients  Ref.
Antimicrobial catheters 
MR CVC  CHG-SSD
CVC
CUA HC payer  PROB, OW, 
SC
Patient
lifetime
Adults at high risk for CR-BSI 
likely to require a triple-lumen, 
noncuffed CVC for >3 d 
27
MR CVC and 
CHG-SSD
CVC
Standard
CVC
CEA HC payer  OW, SC, TH  Duration
hospitalized
Critically ill patients requiring  
a CVC expected to be placed 
>48 h 
29
CHG-SSD
CVC
Standard
CVC
CEA HC payer  PROB, OW, 
SC, TH 
Duration
hospitalized
Patients at high risk for catheter-
related infections requiring short-
term use (2–10 d) of multilumen 
CVCs
30
Aseptic technique 
MSB at CVC 
insertion 
Less
stringent
asepsis
CEA Hospital OW, SC  Duration
hospitalized
Patients requiring short-term 
multilumen CVC (specifically, 
those in ICU, with 
immunosuppression, or receiving 
TPN)
26
Skin preparation and dressing 
CHG skin prep  PI skin 
preparation 
CEA Hospital PROB, OW, 
SC
Duration
hospitalized
Patients requiring either a PVC or 
CVC (considered separately) for 
short-term use (<10 d) 
23
CHG dressing  Standard
dressing
CEA† Hospital OW, MW, SC Duration
hospitalized
Patients at high risk for catheter-
related infections requiring short-
term use (2–10 d) of multilumen 
CVCs
24
Total parenteral nutrition 
TPN
commercial 
bags
TPN glass 
bottles
CMA/CEA Hospital MW, TH  Duration
hospitalized
Patients receiving TPN through  
catheter for severe bowel 
dysfunction secondary to Crohn 
disease, medical ICU patients, 
and surgical ICU patients 
25
Replacement regimen 
Optimal CVC 
change
regimen (10 d, 
5 d) 
3-d change 
regimen
CEA Hospital OW, MW, TH Duration
catheterized
65-year-old man in ICU with 
reversible disease process 
28
*Except for the study in reference 25, which used a regression model, all studies used a decision tree. CR-BSI, catheter-related bloodstream infections; 
Ref., reference; MR, minocycline and rifampicin; CVC, central venous catheter; CHG-SSD, chlorhexidine gluconate/silver sulfadiazine; CUA, cost-utility 
analysis; HC, healthcare; PROB, probabilistic sensitivity analysis; OW, one way; SC, scenario; CEA, cost-effectiveness analysis; TH, threshold; MSB, 
maximal sterile barriers; ICU, intensive-care unit; TPN, total parenteral nutrition; PI, povidone-iodine; CMA, cost-minimization analysis; MW, multi way.  
†Crawford et al. (24) identified their evaluation as a cost-benefit analysis (CBA) but they conducted a cost-effectiveness analysis with health outcomes 
multiplied by a dollar value to produce a monetary valuation of health benefits.Economics of Catheter-related Bloodstream Infections
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conclusions from the analysis would change, and 6 stud-
ies (23,24,26,27,29,30) reported results of scenario analy-
ses, i.e., results where all parameters are set to favor each 
speciﬁ  c intervention in turn (Table 2). The 3 evaluations 
that characterized parameters as distributions (23,27,30) 
also used probabilistic sensitivity analysis, which enabled 
calculation of conﬁ  dence intervals around their point esti-
mates of incremental costs and beneﬁ  ts.
In the 6 evaluations where the intervention was cost-
saving (23,24,26,27,29,30), the conclusions were robust 
to the sensitivity analyses. In the 2 evaluations where an 
incremental cost-effectiveness ratio could be calculated 
(25,28), different conclusions were drawn in different sce-
narios (Table 3). Scenario analyses used in 6 evaluations 
(23,24,26,27,29,30) indicated internal consistency in the 
models, i.e., they behaved logically and as expected. How-
ever, only 1 evaluation (27) made an explicit statement on 
internal consistency about checks performed during the 
model construction and analysis. Authors of 7 evaluations 
discussed caveats to their work (23–27,29,30).
Discussion
We reviewed existing model-based economic evalua-
tions of interventions to prevent CR-BSI. Given the grow-
ing use of economic evidence to inform infection control 
policy (13), the amount of this literature is likely to increase. 
However, critics have questioned the validity of these evalu-
ations. McConnell et al. (31) suggest that “in the absence of 
evidence-based medicine on the effectiveness of antimicro-
bial central venous catheters, on the basis of clinically rel-
evant end points, cost-effectiveness studies are an exercise 
in futility” We would argue that even in this situation the 
best possible decision still needs to be made (11) and that 
evaluations should be judged not on their ability to predict 
the precise value of an intervention but on the “ability of 
a decision model to recommend optimal decisions” (32). 
A decision not to invest in some risk-reducing intervention 
or program is a decision that leads to economic and clinical 
outcomes that are either optimal or not optimal. Economic 
evaluation provides a rational way for the decision maker to 
rank these outcomes, which in the absence of perfect infor-
mation, is of more use than producing a single, potentially 
Table 3. Results of economic evaluations of interventions to prevent CR-BSI* 
Estimated absolute 
incremental benefits 
Intervention
Incidence
CR-BSI, % 
Mortality 
incidence, % 
Estimated
incremental cost  Cost/benefit ratio
Sensitivity 
analysis Ref.
Baseline: CHG-SSD catheter  Variable Not stated  Not stated  27
MR catheter†  0.7 0.009 QALYs    
(–0.009, 0.016)
–$83
($109, –$205) 
Cost saving  Robust
Baseline: standard catheter  3.30 – $469 29
CHG-SSD catheter  1.94 – –$222 Cost saving Robust
MR catheter  2.79 – –$314 Cost saving Robust
Baseline: standard catheter  5.20 0.78 $710 30
CHG-SSD catheter  2.20
(1.2, 3.4) 
0.33
(0.09, 0.78) 
–$262
(–$91, –$522) 
Cost saving  Robust
Baseline: less stringent asepsis  5.30 0.80 $676 26
Maximal sterile barriers  2.49 0.38 –$274 Cost saving Robust
Baseline: Povidone-iodine skin 
preparation 
3.1 0.46 $265 23
Chlorhexidine gluconate  1.6
(0.6, 2.5) 
0.23
(0.07, 0.47) 
–$134
(–$21, –$286) 
Cost saving  Robust
Baseline: standard dressing  5.00 0.05 $514 24‡
Chlorhexidine dressing§  2.63 0.03 –$259 Cost saving Robust
Baseline: glass TPN bottles  10.0 0.50 Not stated  25‡
TPN bags¶  6.67 0.33 Not stated  $28,326/life saved  Variable
Baseline: 5 d  – 0.92 $1,398 28‡
3 d  – 0.02 $8 Variable
10 d  – 0.13 $63
Not clear from source 
what reported cost-
effectiveness ratios 
represented 
Variable
*All estimates have been adjusted to 2005 US dollars. Values in parentheses are 95% confidence intervals. CR-BSI, catheter-related 
bloodstream infections; mortality, CR-BSI attributable mortality; CHG-SSD, chlorhexidine gluconate/silver sulfadiazine; QALYs, quality-adjusted 
life year; MR, minocycline and rifampicin; TPN, total parenteral nutrition.  
†Refers to results for an 8-d duration of catheterization; intervention was cost-saving for durations >8 d and could not be evaluated for <8 d. 
‡Cost year for original analysis not stated; therefore, assumed 1 year before publication. 
§Refers to results using baseline conservative assumptions of 5% CR-BSI incidence rate, 1% CR-BSI attributable mortality rate, and $8,000 
incremental CR-BSI treatment cost. 
¶Refers to results using baseline conservative assumptions of 10% CR-BSI incidence rate, 5% CR-BSI attributable mortality rate, and relative 
reduction in risk for CR-BSI of 0.33. PERSPECTIVE
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misleading, dollar estimate. We critiqued the existing evalu-
ations in terms of their usefulness in providing information 
relevant to clinical practice. We also assessed the quality of 
the evaluations and explored the implication that this would 
have on the information provided to decision makers.
Four interventions were found to be clinically effec-
tive and cost-saving: use of antibiotic-coated catheters 
compared with use of either antiseptic-coated or standard 
catheters, maximal sterile barrier precautions during cath-
eter insertion compared with less stringent aseptic tech-
nique, and use of chlorhexidine gluconate as either a skin 
preparation or impregnated into the insertion site dressing 
compared with use of povidone-iodine skin preparation and 
nonimpregnated dressings. Results of these evaluations are 
robust to a wide range of parameter estimates and assump-
tions. Two other interventions showed health beneﬁ  ts and 
increased costs: use of a 3-day or 10-day catheter replace-
ment regimen rather than replacement every 5 days and use 
of commercially available plastic bags for delivery of total 
parenteral nutrition rather than glass bottles. Conclusions 
about the cost-effectiveness of these interventions changed 
with use of different parameters and assumptions.
Usefulness of Evaluations
We have data on the cost-effectiveness of only 6 in-
terventions. These interventions were evaluated separately 
and not compared with each other. Furthermore, many 
other interventions have been shown to be clinically ef-
fective but, there are no data on their cost-effectiveness. 
This ﬁ  nding is not consistent with current guidelines (2), 
which recommend that “it is logical to use multiple strate-
gies concomitantly.” The 100,000 Lives Campaign is also 
formed on the basis of a group of interventions. The exist-
ing economic evidence is therefore incomplete and cannot 
be used to form a coherent policy for preventing CR-BSI. 
Infection control practitioners and other decision makers 
require information on the relative cost-effectiveness of 
all relevant groups of interventions rather than individual 
strategies (8). A good example of using cost-effectiveness 
to inform a complete policy is provided by Frazier et al 
(33). They evaluated 21 competing strategies for popula-
tion-based colorectal cancer screening and included all rel-
evant screening methods and frequencies. This study pro-
vides policymakers with complete information in as much 
as all available choices have been compared.
The failure to specify baseline values (i.e., the value 
authors believe is most likely) for model parameters is also 
problematic. Instead of estimating a baseline model and 
then testing whether the conclusions are robust to high and 
low values, some authors report all possible results on the 
basis of all possible values for some parameters. This shifts 
the responsibility of interpreting the results to the reader. 
The failure to describe how high and low values were cho-
sen for key parameters (i.e., the double-it and half-it ap-
proach) compounds the problem.
Table 4. Assessment of published evaluations and good practice 
criteria for decision models 
Attributes of good practice criteria 
No. models meeting 
criterion, n = 8
Structure
Perspective specified  8
Description of strategies/comparators  8
Diagram of model/disease pathways  6
Development of model structure and 
assumptions discussed 
4
Data
Table of model input parameters 
presented
5
Source of parameters clearly stated  8
Model parameters expressed as 
distributions
3
Model assumptions discussed  7
Sensitivity analysis performed  8
Key drivers/influential parameters 
identified
6
Consistency 
Statement about test of internal 
consistency undertaken 
1
Table 5. Variation between economic evaluations in baseline parameter estimates* 
Baseline parameters 
No. times identified 
as key parameter 
No. different 
estimates
Minimum
estimate Maximum estimate 
Median
estimate
Epidemiologic
Incidence of CR-BSI  6/8 8/8 3.1% 8.0% 5.3%
Effectiveness of the intervention  6/8 Will vary according to intervention 
Attributable mortality  2/7 5/7 5% 15% 14%
Incidence of localized insertion site 
infection
0/5 4/5 5% 50% 20%
Cost
Cost of CR-BSI  6/8 6/8 US $2,820  US $13,000  US $10,531 
Cost of localized insertion site 
infection
0/5 3/5 US $195  US $435  US $280 
Cost of intervention   2/8 Will vary according to intervention 
Cost of other complications  1/3 Will vary according to complications considered 
*All cost estimates adjusted to 2005 US dollars. Values for parameters are the baseline estimate used in the model (the same patterns of variation were 
observed with the ranges used for sensitivity analysis). CR-BSI, catheter-related bloodstream infections. Economics of Catheter-related Bloodstream Infections
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Assessing Quality
There was a lack of transparency in the development 
of model structure. Model structure may have been driven 
by availability of data rather than careful review of the nat-
ural progression of the disease. This could undermine the 
external consistency of the evaluations as they appear to 
users. The choice of short-time horizons and narrow eco-
nomic perspectives inhibits the usefulness of these evalua-
tions by excluding relevant costs and health outcomes from 
the analysis. The current evidence may represent a blink-
ered view of the problem and how it should be managed. 
This situation in turn reduces the extent to which the value 
of infection control can be compared with other healthcare 
spending such as cardiac surgery and diabetes prevention.
The quality of data incorporated in the models is high-
ly variable. The authors of 7 studies (23,24,26–30) suggest 
that their results are compromised by an absence of high-
quality or precise information, often for key parameters in 
the model. This ﬁ  nding leads to some skepticism about the 
results (31). Researchers are attempting to provide better 
estimates of the health and economic outcomes attributable 
to CR-BSI (34). However, a model should not be criticized 
on the basis of the quality of data used per se. Rather, it 
should be judged on the techniques used to identify and in-
corporate the highest quality appropriate and relevant data 
possible (35) for all parameters, not just those relating to 
effectiveness. Given the lack of information provided by 
the authors about this process, a more systematic approach 
to selecting evidence needs to be introduced. Generic tools 
such as the hierarchy used here (19) are useful to judge evi-
dence quality, but this may need to be supplemented with 
tools such as the hierarchy of quasi-experimental study de-
signs, given the prevalence of the use of these designs in 
the infection control literature (36). Where multiple pieces 
of relevant information are available, techniques exist for 
the synthesis of diverse evidence (37).
Given the variations in data quality, selecting  the best 
evidence and then propagating the effect of uncertainty in 
this evidence to the conclusions drawn are important. A 
good method is probabilistic sensitivity analysis (38). This 
method was used in 3 evaluations (23,27,30). This tech-
nique characterizes parameter estimates as distributions 
rather than discrete values and conducts multiple simula-
tions of the model that draw different parameter values 
each time from the distributions. This enables the uncer-
tainty around the costs and beneﬁ  ts of a given interven-
tion to be described and the relative contribution to all un-
certainty arising from each parameter to be estimated. The 
next step, which was not conducted for any evaluation, is to 
estimate the value of collecting more data to inform these 
parameters (39). This step would be particularly relevant 
to the key parameters identiﬁ  ed in this review. The current 
methods used to derive estimates of costs and deaths at-
tributable to CR-BSI are subject to some bias and may not 
make intuitive sense to clinicians (31). This issue is prob-
lematic because these methods are important components 
in the model, often driving the changes in costs and bene-
ﬁ  ts, and it is likely this ﬁ  nding partly explains why so many 
interventions appear cost-saving.
This review has some limitations. Despite use of a broad 
search strategy, we may not have identiﬁ  ed all model-based 
economic evaluations in this area; some evaluations may 
not have been published or are available only as abstracts. 
Also, our assessment of the quality of evaluations using the 
good practice criteria may reﬂ  ect the way evaluations are 
reported rather than conducted. In fact, word limits often 
prevent authors from providing a full description of meth-
ods. However, any indication that a criterion was addressed 
was taken as an evaluation that met that attribute.
Conclusion
We do not have a comprehensive understanding of the 
economics of preventing CR-BSI. Policymakers and regu-
latory agencies are unable to recommend the best approach 
to mitigate risks for CR-BSI in patients in intensive-care 
units. Those who propose to undertake research in this area 
would beneﬁ  t from a careful consideration of this review. 
Modelers should collaborate and aim to develop a consen-
Table 6. Ranks of evidence for parameters used in the decision models* 
Evidence ranking 
Clinical effectiveness 
of intervention, n = 8 
Baseline
incidence
CR-BSI, n = 8 
Attributable
mortality, 
n = 7 
Incidence localized 
insertion site 
infection, n = 5 
Cost of
CR-BSI,
n = 8 
Cost of 
intervention,
n = 8 
High quality 
Rank 1 5 1 – – 2 –
Rank 2 1 1 1 – 1 7
Medium quality 
Rank 3 – 1 1 – 2 –
Low quality 
Rank 4 1 4 4 4 2 –
Rank 5 – 1 1 1 – –
Rank 6 – – – – – –
Unclear 1 – – – 1 1
*CR-BSI, catheter-related bloodstream infections. PERSPECTIVE
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sus on key issues such as model structure, data sources, 
and evaluation methods. This activity is promoted by the 
International Society for Pharmacoeconomics and Out-
comes Research and The Cancer Intervention and Surveil-
lance Modeling Network. Ultimately, the best policy for 
preventing CR-BSI will emerge from an iterative process 
that includes researchers, clinicians, modelers, and deci-
sion makers.
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